title: Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009: comments on the article by M Neovius et al.
authors.forename: H
authors.initials: H
authors.lastname: Ohlsson
authors.forename: J
authors.initials: J
authors.lastname: Merlo
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D003695:Delivery of Health Care; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000706:statistics & numerical data; D011307:Drug Prescriptions / Q000592:standards* / Q000706:statistics & numerical data; D000069285:Infliximab; D040541:Marketing / Q000191:economics* / Q000706:statistics & numerical data; D017062:Small-Area Analysis; D013548:Sweden
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000069285:Infliximab; D000068879:Adalimumab